125 related articles for article (PubMed ID: 28150169)
1. KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.
Sullivan I; Salazar J; Arqueros C; Andrés M; Sebio A; Majem M; Szafranska J; Martínez E; Páez D; López-Pousa A; Baiget M; Barnadas A
Clin Transl Oncol; 2017 Jul; 19(7):884-890. PubMed ID: 28150169
[TBL] [Abstract][Full Text] [Related]
2. NKX2-1 expression as a prognostic marker in early-stage non-small-cell lung cancer.
Moisés J; Navarro A; Santasusagna S; Viñolas N; Molins L; Ramirez J; Osorio J; Saco A; Castellano JJ; Muñoz C; Morales S; Monzó M; Marrades RM
BMC Pulm Med; 2017 Dec; 17(1):197. PubMed ID: 29237428
[TBL] [Abstract][Full Text] [Related]
3. The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.
Honda T; Seto K; Endo S; Takemoto A; Tanimoto K; Kobayashi M; Kitano M; Sakakibara R; Mitsumura T; Ishibashi H; Inazawa J; Tanaka T; Miyazaki Y; Okubo K
Cancer Med; 2023 Oct; 12(19):19406-19413. PubMed ID: 37712717
[TBL] [Abstract][Full Text] [Related]
4. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
Iams WT; Yu H; Shyr Y; Patil T; Horn L; McCoach C; Kelly K; Doebele RC; Camidge DR
Clin Lung Cancer; 2018 Nov; 19(6):531-543. PubMed ID: 30197261
[TBL] [Abstract][Full Text] [Related]
5. Five-year survival of resectable stage IIIA non-small cell lung cancer in Brazil.
de Barros MLGP; Silva VG; Moreira FR; Perez SV; Younes RN; Abrão FC
J Surg Oncol; 2023 Dec; 128(7):1195-1204. PubMed ID: 37448240
[TBL] [Abstract][Full Text] [Related]
6. A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
Jones GD; Brandt WS; Shen R; Sanchez-Vega F; Tan KS; Martin A; Zhou J; Berger M; Solit DB; Schultz N; Rizvi H; Liu Y; Adamski A; Chaft JE; Riely GJ; Rocco G; Bott MJ; Molena D; Ladanyi M; Travis WD; Rekhtman N; Park BJ; Adusumilli PS; Lyden D; Imielinski M; Mayo MW; Li BT; Jones DR
JAMA Surg; 2021 Feb; 156(2):e205601. PubMed ID: 33355651
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
Cancer Lett; 2024 Jul; 594():216984. PubMed ID: 38797230
[TBL] [Abstract][Full Text] [Related]
8. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.
Masago K; Fujita S; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Ichikawa M; Mio T; Mishima M
Cancer Sci; 2009 Oct; 100(10):1917-22. PubMed ID: 19594543
[TBL] [Abstract][Full Text] [Related]
9. Air bronchogram on chest CT in radiological pure-solid appearance lung cancer: Correlation analysis with genetic pathological features and survival outcomes.
Wang Z; Zhu W; Yang M; Du H; Zhou F; Song N; Wan Z; Zhu J; Li W
Eur J Radiol; 2023 Dec; 169():111194. PubMed ID: 37976762
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer.
Iwasaki M; Ishihara S; Okada S; Shimegi R; Shimomura M; Inoue M
Ann Surg Oncol; 2022 Sep; 29(9):5699-5707. PubMed ID: 35653068
[TBL] [Abstract][Full Text] [Related]
11. BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
Bucciarelli PR; Tan KS; Chudgar NP; Brandt W; Montecalvo J; Eguchi T; Liu Y; Aly R; Travis WD; Adusumilli PS; Jones DR
J Thorac Oncol; 2018 Jan; 13(1):73-84. PubMed ID: 29097253
[TBL] [Abstract][Full Text] [Related]
12. Relapse-related molecular signature in early-stage lung adenocarcinomas based on base excision repair, stimulator of interferon genes pathway and tumor-infiltrating lymphocytes.
Yang B; Rao W; Luo H; Zhang L; Wang D
Cancer Sci; 2020 Oct; 111(10):3493-3502. PubMed ID: 32654272
[TBL] [Abstract][Full Text] [Related]
13. Effect of initial recurrence site on the prognosis of different tissue types of non-small cell lung cancer: a retrospective cohort study.
Li Y; Liu L; You R; Li Q; Jiang Z; Pu H; Li Z; Chen X
World J Surg Oncol; 2023 Nov; 21(1):360. PubMed ID: 37986082
[TBL] [Abstract][Full Text] [Related]
14. The lung microbiome, peripheral gene expression, and recurrence-free survival after resection of stage II non-small cell lung cancer.
Peters BA; Pass HI; Burk RD; Xue X; Goparaju C; Sollecito CC; Grassi E; Segal LN; Tsay JJ; Hayes RB; Ahn J
Genome Med; 2022 Oct; 14(1):121. PubMed ID: 36303210
[TBL] [Abstract][Full Text] [Related]
15. [The effect of tumor spread through air spaces on the prognosis of patients with stage Ⅰ non-small cell lung cancer: a meta-analysis].
Nurmamat A; Hu Y; Mamatabdulla M; Che Y; Zhang LW; Zhang HP
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3683-3690. PubMed ID: 38044614
[No Abstract] [Full Text] [Related]
16. Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer.
Motono N; Mizoguchi T; Ishikawa M; Iwai S; Iijima Y; Uramoto H
Lung; 2023 Dec; 201(6):603-610. PubMed ID: 37906295
[TBL] [Abstract][Full Text] [Related]
17. Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer.
Jang HJ; Lee HS; Burt BM; Lee GK; Yoon KA; Park YY; Sohn BH; Kim SB; Kim MS; Lee JM; Joo J; Kim SC; Yun JS; Na KJ; Choi YL; Park JL; Kim SY; Lee YS; Han L; Liang H; Mak D; Burks JK; Zo JI; Sugarbaker DJ; Shim YM; Lee JS
Gut; 2017 Feb; 66(2):215-225. PubMed ID: 27507904
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
Lu J; Feng Y; Guo K; Sun L; Ruan S; Zhang K
J Cancer Res Clin Oncol; 2024 Jan; 150(1):25. PubMed ID: 38252173
[TBL] [Abstract][Full Text] [Related]
19. Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer.
Pankratz VS; Sun Z; Aakre J; Li Y; Johnson C; Garces YI; Aubry MC; Molina JR; Wigle DA; Yang P
J Thorac Oncol; 2011 Sep; 6(9):1488-95. PubMed ID: 21792076
[TBL] [Abstract][Full Text] [Related]
20. Association between the Preoperative Standard Uptake Value (SUV) and Survival Outcomes after Robotic-Assisted Segmentectomy for Resectable Non-Small Cell Lung Cancer (NSCLC).
Aboukheir Aboukheir A; Villanueva EQ; Garrett JR; Moodie CC; Tew JR; Toloza EM; Fontaine JP; Baldonado JJAR
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
